Trending Up0.2750 (1.7394%)
  • Bid / Lots
    15.8800/ 2
  • Ask / Lots
    16.0600/ 1
  • Open / Previous Close
    15.7600 / 15.8100
  • Day Range
    Low 15.3000
    High 16.0850
  • 52 Week Range
    Low 12.2850
    High 37.1100
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 15.81
09:32 ET13615.76
09:35 ET10015.72
10:11 ET10015.79
10:45 ET10015.71
10:47 ET10015.71
10:51 ET50015.89
11:03 ET10015.83
11:12 ET10015.875
11:41 ET10015.78
11:48 ET10015.71
12:03 ET10015.64
12:21 ET10015.62
12:42 ET20015.61
12:44 ET30015.6152
01:02 ET70015.4
01:09 ET40015.55
01:22 ET10015.41
01:27 ET30015.485
01:40 ET10015.43
01:44 ET10015.57
01:56 ET10015.48
01:58 ET10015.34
02:12 ET10015.35
02:25 ET1709515.385
02:27 ET1827415.3
02:30 ET15015.47
02:32 ET50015.465
02:34 ET20115.49
02:38 ET35015.58
02:39 ET10015.72
02:41 ET40015.8
02:43 ET70015.91
02:45 ET10015.92
02:48 ET40015.955
02:50 ET10015.865
02:52 ET10015.94
02:54 ET20015.955
02:56 ET30015.95
02:57 ET10016.085
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVERA
Vera Therapeutics Inc
United StatesPMVP
PMV Pharmaceuticals Inc
United StatesVIGL
Vigil Neuroscience Inc
United StatesBTAI
BioXcel Therapeutics Inc
United StatesTRDA
Entrada Therapeutics Inc
United StatesALT
Altimmune Inc
As of 2022-11-29

Company Information

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. It is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus. The Company is also planning to initiate a Phase III clinical trial of atacicept as a potential treatment for patients with LN, a severe renal manifestation of Systemic Lupus Erythematosus (SLE).

Contact Information

8000 Marina Boulevard Suite 120, 3Rd FloorBRISBANE, CA, United States 94005


Independent Chairperson of the Board of Directors
Kurt Von Emster
President, Chief Executive Officer, Founder, Director
Marshall Fordyce
Chief Financial Officer
Sean Grant
Senior Vice President - Finance, Chief Accounting Officer
Joseph Young
Senior Vice President - Development Operations
Tom Doan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.